Tag: Keytruda

Triple-negative breast cancer (TNBC) remains one of the most challenging and most malignant subtypes of breast cancer to treat. TNBC represents a heterogeneous group...

Phase 3 Study Supports Sacituzumab Govitecan + Pembrolizumab as a Potential New Standard of Care in First-line PD-L1+ mTNBC

ESMO 2025: Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care

The Phase 3 EV-303 is an ongoing clinical trial evaluating enfortumab vedotin (Padcev™; Pfizer and Astellas Pharma), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with pembrolizumab (Keytruda™; Merck & Co), a PD-1 inhibitor, as neoadjuvant and adjuvant treatment (before and after surgery) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for or declined cisplatin-based chemotherapy.

During the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) which will take place May 30 – June 3, 2025, in Chicago, Illinois, Rakuten Medical* will be presenting a Trial in Progress poster with updates of the company's ongoing global Phase 3 clinical trial evaluating ASP-1929 photoimmunotherapy in combination with the anti-PD-1 pembrolizumab (Keytruda®; Merck & Co / MSD) as a first-line therapy for patients with recurrent head and neck squamous cell carcinoma (HNSCC).

China Approves Combination of Enfortumab Vedotin + Pembrolizumab for the Treatment of Advanced Bladder Cancer

During the upcoming European Society for Medical Oncology (ESMO) Congress 2024, being held September 13-17, 2024 in Barcelona, Spain, Pfizer is presenting encouraging early results for preliminary efficacy and safety data for disitamab vedotin* in combination with pembrolizumab (Keytruda®; Merck & Co), and results from an additional analysis from the pivotal EV-302 trial supporting the combination of enfortumab vedotin (Padcev®; Astellas/Pfizer) and pembrolizumab (Keytruda®; Merck & Co) as a new standard of care for patients with previously untreated la/mUC.

During the upcoming 2024 annual meeting of the American Society of Clinical Oncology (ASCO) Annual Meeting, been held from May 31st - June 4th, Astellas...

At the recently held annual meeting of the American Association for Cancer Research (AACR), positive Phase 2 trial (NCT03835819) results of the combination of mirvetuximab soravtansine and the immune checkpoint inhibitor (ICI) Pembrolizumab (Keytruda®; Merck & Co) in the treatment of folate receptor-alpha (FR-α) positive recurrent microsatellite stable / mismatch repair proficient serous endometrial cancer were presented.

Enfortumab vedotin + Pembrolizumab Approved by US FDA as the First and Only ADC + PD-1 Combination to Treat Advanced Bladder Cancer